Publications by authors named "D Laufer"

Article Synopsis
  • - Vaccine priming using germline-targeting immunogens could enhance the development of precision vaccines for serious human diseases, as shown in a clinical trial of eOD-GT8 60mer.
  • - The trial found that participants receiving a higher vaccine dose had more VRC01-class bnAb-precursor B cells compared to those receiving a lower dose, but the differences were primarily linked to their IGHV1-2 genotypes.
  • - The study highlights the importance of understanding genetic variations in immune response (specifically immunoglobulin alleles) when creating and testing new vaccines in clinical settings.
View Article and Find Full Text PDF

Rhizoctonia crown and root rot (RCRR), caused by , can cause severe yield and quality losses in sugar beet. The most common strategy to control the disease is the development of resistant varieties. In the breeding process, field experiments with artificial inoculation are carried out to evaluate the performance of genotypes and varieties.

View Article and Find Full Text PDF

The lymph node (LN) is a critical biological site for immune maturation after vaccination as it includes several cell populations critical for priming the antibody response. Here, we present a protocol for sampling the LN and isolating cell populations to evaluate immunogens targeting germline cells. We describe steps for media and tube preparation and sample collection using an ultrasound-guided LN fine-needle aspiration procedure.

View Article and Find Full Text PDF

The engineered outer domain germline targeting version 8 (eOD-GT8) 60-mer nanoparticle was designed to prime VRC01-class HIV-specific B cells that would need to be matured, through additional heterologous immunizations, into B cells that are able to produce broadly neutralizing antibodies. CD4 T cell help will be critical for the development of such high-affinity neutralizing antibody responses. Thus, we assessed the induction and epitope specificities of the vaccine-specific T cells from the IAVI G001 phase 1 clinical trial that tested immunization with eOD-GT8 60-mer adjuvanted with AS01.

View Article and Find Full Text PDF
Article Synopsis
  • Vaccine priming immunogens that target specific immune responses show potential for creating effective vaccines against major diseases.
  • A clinical trial of the eOD-GT8 60mer found that participants receiving a higher dose had more B cells related to broadly neutralizing antibodies (bnAbs) than those on a lower dose.
  • The differences in response were more linked to genetic variations in immunoglobulin alleles among participants than to the vaccine dose, highlighting the importance of considering genetic diversity in vaccine design and testing.
View Article and Find Full Text PDF